SUMMARY Laboratory measurements were compared in paired samples from 50 patients included in a double-blind placebo controlled trial of methylprednisolone in the treatment of multiple sclerosis. Cerebrospinal fluid total cell count, IgG and C9 indices, and percentage of peripheral blood OKT8 positive cells were abnormal at entry and returned closer to the normal range after active than placebo treatment, but the differences were not statistically significant. The percentage of peripheral blood OKT4 positive cells was normal at entry as was the amplitude of visual evoked potentials, whereas their latency was prolonged; these measurements were each uninfluenced by methylprednisolone. Corticosteroids might act merely by influencing oedema, but the laboratory results suggest that methylprednisolone affects immunological events which underly rapid onset and recovery of symptoms in patients with -multiple sclerosis; additional forms of treatment are needed to maintain these clinical and immunological effects. symptoms and in turn, the clinical method may be a poor guide to disease activity. In order indirectly to investigate the mechanism of action of methylprednisolone in multiple sclerosis, we have recorded the amplitude and latency of visual evoked potentials, enumerated circulating T cell sub-population phenotypes, measured cerebrospinal fluid (CSF) total cell content and derived IgG and C9 indices, before and after active or placebo treatment with methylprednisolone in patients with acute relapsing and chronic progressive forms of the disease.
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The development of strategies for treatment in multiple sclerosis is limited by poor understanding of the sequence of events leading to production of symptoms. High dose intravenous methylprednisolone improves acute and chronic symptoms in multiple sclerosis compared with placebo treated controls' and in most patients these effects occur within one week of starting treatment suggesting that corticosteroids influence rapidly reversible mechanisms of myelin injury. Although this group of drugs has been used in the treatment of multiple sclerosis for many years2 the mode of action has rarely been investigated. Symptomatic improvement in demyelination could result from resolution of oedema, (0); counting by flow cytometry on a Becton Dickinson FACS methylprednisolone, chronic progression (C); placebo, acute III. The number of fluorescent cells/1000 was estimated after-relapse ( 0); placebo, chronic progression (El). Cases in subtraction of background counts which ranged from whom measurements did not change appear on, or close to, <0-5-2%, and were expressed as a percentage of total the diagonal line. A lower result after treatment is indicated mononuclear cells. The latency and amplitude of the P100 by a point below, and an increased measurement by a point response were recorded from an active electrode placed 5 cm above this line. Statistical analysis ofresults is based on one above the inion with a reference electrode 10cm above the way analysis of variance (see text). nasion, after pattern reversal stimulus using an OTE myograph/evoked potential system (BASIS); 100 responses v0duals was 5 cells (95% of cell counts are in the range were averaged. Our normal range for the amplitude and 05-46). The effect of treatment with methyllatency of the P100 response is 3 -2-15 5 mV and 88-105 ms prednisolone was to lower the cell count to 33-4% less respectively.
than expected on placebo treatment ( (active eight, placebo 11) and fell by this amount in four (active three, placebo one) patients. The right eye amplitude rose by > 005 mV in eight (active five, placebo three), remained stable in seven (active three, placebo four) and fell by this amount in 12 (active six, placebo six) individuals. The mean latency from 25 left eyes was 1 14 ( ± 14-9) ms before treatment and the geometric mean amplitude 5 82mV (95% of the amplitudes are in the range 2-69-126 mV). The effect of treatment was to increase the latency to 11 ms more than expected on placebo treatment. (t = 0 67); the equivalent change in amplitude was -08% (t = 0 04). The left eye latency increased by > 5 ms in three (active), remained stable in 19 (active nine, placebo 10) and fell by this amount in three (active one, placebo two) individuals. The left eye amplitude fell by > 005 mV in 10 (active six, placebo four) remained stable in seven (active two, placebo five) and rose by this amount in eight (active five, placebo three) individuals (not shown in figures). These differences are not significant.
Discussion
Patients with acute relapsing and chronic progressive multiple sclerosis improved clinically following treatment with high dose methylprednisolone in a doubleblind placebo controlled trial,' CSF total cell count, IgG and C9 indices and the percentage of peripheral blood OKT8 positive cells were abnormal at entry and returned closer to the normal range after active than placebo treatment but the differences were not statistically significant. The percentage of peripheral blood OKT4 positive cells was normal at entry, as was the amplitude of visual evoked potentials but not their latency; each was uninfluenced by methylprednisolone.
Difficulties arise in interpreting these laboratory results not least because the physical basis for symptoms is poorly understood during both the relapsing/remitting and progressive phases of the disease. Morphologically there is an orderly progression from lymphocytic infiltration of the early lesion to development of severe demyelination, axonal loss, oligodendrocyte depletion, astrocytosis and insignificant remyelination seen in chronic plaques; conversely, the symptoms in multiple sclerosis are usually intermittent and recover spontaneously in the early stages. Factors which determine progressive symptoms, whether from onset or after a period of relapses, are unknown but the available evidence suggests that the switch to progression does not signify a change in the disease process; for this reason we have assessed the laboratory effects of methylprednisolone in multiple A double-blind controlled trial ofhigh dose methylprednisolone in multiple sclerosis: 2. laboratory results 521 sclerosis patients irrespective of clinical classification.
Several mechanisms have been proposed for symptomatic recovery including resolution of oedema, synaptic reorganisation6 and removal of complement-dependent neuro-electric blocking factors.7 But none of these can explain all the clinical and pathological observations. One interpretation is that the symptoms of multiple sclerosis are frequently not due to demyelination defined morphologically but arise from mechanisms of myelin injury which are fully reversible. We have suggested that complement activation leading to formation of membrane attack complexes mediates reversible and irreversible lesions which in combination, could account for the time course of symptoms8 9 during the relapsing and progressive phases.
Corticosteroid treatment in patients with multiple sclerosis reduces intrathecal IgG production, reflected by changes in CSF IgG concentration, IgG index, IgG synthesis rate and intensity or number of oligoclonal bands; one or other of these changes is observed following oral, intramuscular, intravenous or intrathecal treatment'0 -12 but there is no effect on CSF cell count12 and no clear pattern emerges from comparing the reported effects of corticosteroids, or other immunological agents, on number or function of B and T lymphocytes and their subpopulations.13 -17 A reduction in latency of abnormal visual evoked potentials has been observed during serial studies of untreated patients'8 and during combined immunosuppressive treatment'9 but the electrophysiological effects of methylprednisolone are unknown. In our study, corticosteroids produced rapid clinical improvement during relapse and in the progressive phase and there were simultaneous changes in several laboratory indices shown to be abnormal before treatment. The possibility exists that these changes would have been statistically significant if we had obtained paired samples from all participants or made post-treatment assessments on completion of the five day course.
Although the latency of visual evoked reponses does not necessarily reflect changes in conduction throughout the nervous system, our results provide no evidence that rapid symptomatic changes occur primarily as a result of altered physiological properties in demyelinated axons. The rapid clinical improvement could be accounted for by resolution of oedema, present at least in acute plaques, in which case no alteration in immunological abnormalities would be expected; none were observed in our study. The selective effect of methylprednisolone in patients with multiple sclerosis could be due to a direct effect on skeletal muscle, similar to the action of dantrium sodium. But collectively the trend towards correction of abnormal peripheral blood OKT8 positive cells, CSF pleocytosis and IgG or C9 indices suggests that the mechanism of action may depend partly on a modification of immunological events directly involved in tissue injury. Specifically, the most significant effect of methylprednisolone we observed was an increase in C9 index; this finding is consistent with inhibition of intrathecal complement activation,8 9 an event which normally leads to cell lysis. The rapidly reversible-consequences of membrane attack complex formation on cell injury may be mediated by a rise in intracellular calcium20 -23 and in the special situation of partially demyelinated axons, " this would be expected temporarily to interfere with the propagation of nerve impulses. It has recently been demonstrated that conduction in the central nervous system, reflected by latency of visual evoked potentials, improved in patients with multiple sclerosis during infusion of the calcium channel blocker verapamil.24 High-dose intravenous methylprednisolone might achieve similar, but less immediate effects by inhibiting complement activation, thereby preventing transient changes in the calcium ion environment of myelinated axons.
Corticosteroids appear temporarily to influence the disease process in multiple sclerosis but they do not produce a lasting effect on the clinical or immunological manifestations of the disease. Our clinical and laboratory results endorse the immunological approach to treatment, but the use of corticosteroids may require maintenance treatment with other immunological agents in order to influence the long-term course of the disease.
